NextCure prices 2.5M shares at $8.52 in private placement

NextCure (NXTC) entered into definitive agreements with the participation of certain institutional and accredited investors, including Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, LP., Exome Asset Management as well as other healthcare focused funds, for the purchase and sale of an aggregate of 2,523,477 shares of common stock at a purchase price of $8.52 per share of common stock in a private placement priced at-the-market under Nasdaq rules. The private placement is expected to close on or about November 13, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $21.5M, prior to deducting placement agent’s fees and other offering expenses payable by the Company.